These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24334184)

  • 1. Lack of effect of doxycycline on trough concentrations of protease inhibitors or non-nucleoside reverse transcriptase inhibitors in HIV-infected patients.
    Abgrall S; Le Bel J; Lele N; Laouénan C; Eychenne N; Mentré F; Peytavin G; Bouchaud O;
    HIV Clin Trials; 2013; 14(6):313-8. PubMed ID: 24334184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice.
    Moltó J; Blanco A; Miranda C; Miranda J; Puig J; Valle M; DelaVarga M; Fumaz CR; Barbanoj MJ; Clotet B
    Br J Clin Pharmacol; 2006 Nov; 62(5):560-6. PubMed ID: 17061963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice.
    Moltó J; Blanco A; Miranda C; Miranda J; Puig J; Valle M; Delavarga M; Fumaz CR; Barbanoj MJ; Clotet B
    Br J Clin Pharmacol; 2007 Jun; 63(6):715-21. PubMed ID: 17223856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of various antiretroviral drugs and their plasma concentrations on plasma lipids in heavily pretreated HIV-infected patients.
    Clevenbergh P; Garraffo R; Dellamonica P
    HIV Clin Trials; 2003; 4(5):330-6. PubMed ID: 14583849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Warfarin-antiretroviral interactions.
    Liedtke MD; Rathbun RC
    Ann Pharmacother; 2009 Feb; 43(2):322-8. PubMed ID: 19196837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor.
    Solas C; Poizot-Martin I; Drogoul MP; Ravaux I; Dhiver C; Lafeuillade A; Allegre T; Mokhtari M; Moreau J; Lepeu G; Petit N; Durand A; Lacarelle B
    Br J Clin Pharmacol; 2004 Apr; 57(4):436-40. PubMed ID: 15025741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.
    Winston A; Bloch M; Carr A; Amin J; Mallon PW; Ray J; Marriott D; Cooper DA; Emery S
    J Antimicrob Chemother; 2005 Aug; 56(2):380-7. PubMed ID: 15996972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.
    Winston A; Jose S; Gibbons S; Back D; Stohr W; Post F; Fisher M; Gazzard B; Nelson M; Gilson R; Orkin C; Johnson M; Palfreeman A; Chadwick D; Leen C; Schwenk A; Anderson J; Gompels M; Dunn D; Khoo S; Sabin C;
    J Antimicrob Chemother; 2013 Jun; 68(6):1354-9. PubMed ID: 23435690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.
    Fabbiani M; Di Giambenedetto S; Bracciale L; Bacarelli A; Ragazzoni E; Cauda R; Navarra P; De Luca A
    J Antimicrob Chemother; 2009 Jul; 64(1):109-17. PubMed ID: 19398461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
    Joly V; Descamps D; Yeni P
    AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical guidelines to interpret plasma concentrations of antiretroviral drugs.
    Kappelhoff BS; Crommentuyn KM; de Maat MM; Mulder JW; Huitema AD; Beijnen JH
    Clin Pharmacokinet; 2004; 43(13):845-53. PubMed ID: 15509183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
    Joly V; Yeni P
    Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?
    Dahri K; Ensom MH
    Clin Pharmacokinet; 2007; 46(2):109-32. PubMed ID: 17253884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
    Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
    HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems.
    Schoenenberger JA; Aragones AM; Cano SM; Puig T; Castello A; Gomez-Arbones X; Porcel JM
    Ther Drug Monit; 2013 Feb; 35(1):71-7. PubMed ID: 23188184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
    MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
    Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evidence of interaction between itraconazole and nonnucleoside reverse transcriptase inhibitors in HIV-infected patients with disseminated histoplasmosis.
    Andrade RA; Evans RT; Hamill RJ; Zerai T; Giordano TP
    Ann Pharmacother; 2009 May; 43(5):908-13. PubMed ID: 19401476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.
    Imaz A; Llibre JM; Navarro J; Curto J; Clotet B; Crespo M; Ferrer E; Saumoy M; Tiraboschi JM; Murillo O; Podzamczer D
    Antivir Ther; 2014; 19(6):569-77. PubMed ID: 24458091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.